NY-SK-CAPITAL-PARTNERS
The Heubach Group (“Heubach”, the “Company”), a leading global producer of pigments and SK Capital Partners (“SK Capital”), a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, announced today the completion of the acquisition of Clariant’s Global Colorants Business (“Clariant Pigments”). The combined business will operate under the Heubach brand, creating a global pigment technology and industry leader.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211231005108/en/
The newly combined Heubach Group is a leading global provider of comprehensive color solutions, supplying a broad portfolio of organic, inorganic, and anti-corrosive pigments, pigment preparations, dyes, colorants and specialty materials. The Company is a technological and quality leader and operates its global business from nineteen manufacturing facilities across Europe, the Americas, Asia and Africa, employing approximately 3,000 people. The headquarters of the Heubach Group will be established in Vienna, Austria.
Johann Heubach, of the Heubach Group, stated, “The new Heubach is a world-class organization with great talent, technology and assets. For us, product excellence and sustainability are core. We are well-positioned to create significant value for our customers and business partners across the many industries we serve.”
Aaron Davenport, a Managing Director of SK Capital, noted, “The combination of Heubach and Clariant Pigments creates an industry leader committed to the highest standards in manufacturing, quality and service. We look forward to supporting management in the growth and improvement of the Company by investing into talent, innovation and market expansion.”
The Heubach Group is excited to announce the appointment of Stefan Doboczky as Chief Executive Officer of the Heubach Group, effective January 10, 2022. Mr. Doboczky joins the Heubach Group having most recently served as CEO of Lenzing AG, a global leader of cellulosic fibers and biochemicals. Prior to Lenzing, Mr. Doboczky was member of the Managing Board of Royal DSM, the Dutch Life Science and Material Science Group, where he spent almost two decades in various general management roles. Mr. Doboczky holds a PhD in Natural Science from the Technical University of Vienna (A), as well as an MBA from IMD in Lausanne (CH). Stefan Doboczky noted, “I am very excited to join the new Heubach Group. I am convinced that by combining these successful businesses we will create a powerful offering for our customers in the pigment and colorant space.”
The Valence Group of Piper Sandler & Co., BofA Securities and Citigroup served as financial advisors to Heubach and SK Capital. Committed financing for the transaction was provided by BofA Securities, Citigroup, HSBC, KeyBanc, Citizens, ING and MUFG. Lenz & Staehelin AG and Kirkland & Ellis LLP acted as legal counsel to Heubach and SK Capital. Milbank LLP acted as legal counsel to Heubach. Homburger AG acted as legal counsel to Clariant and Deutsche Bank AG served as Clariant’s financial advisor.
About Heubach Group
With a tradition of delivering excellence that stretches back over 200 years, the Heubach name is synonymous with innovation, attention to customer needs and reliability in creating colors. Today’s Heubach is a global industry leader in the field of pigments, pigment preparations, dyes, colorants and specialty materials. Heubach is committed to reliable supply of high-quality materials to meet customers demanding production environments. Sustainability is a part of the Heubach DNA. Heubach has a global manufacturing footprint including 19 facilities around the globe and generates approximately €1 billion in annual sales. For more information, please visit www.heubachcolor.com .
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, chemicals and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $14 billion annually, employs more than 20,000 people globally and operates 191 plants in 32 countries. The firm currently has greater than $5 billion of assets under management. For more information, please visit www.skcapitalpartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211231005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blackstone Credit & Insurance Appoints Laura Coady as Global Head of CLOs and European Head of Liquid Credit Strategies3.11.2025 13:10:00 CET | Press release
Blackstone (NYSE: BX) announced today that Laura Coady, formerly Head of International Securitised Markets and Global Head of CLOs at Jefferies, has joined Blackstone Credit & Insurance (“BXCI”) as Global Head of CLOs and European Head of Liquid Credit Strategies (LCS). Based in London, Coady will oversee BXCI’s CLO activity globally, including CLO formation and investing, and lead the liquid credit business in Europe. BXCI’s LCS business manages $120 billion across corporate bonds, leveraged loans, CLOs and Multi-Asset Credit. Blackstone is the largest global manager of CLOs and loans, and the most active loan trader. The firm set a record for global annual CLO issuance in 2024, beating the previous record set by Blackstone in 2021. Dan Leiter, Head of International and Global Head of Liquid Credit Strategies for BXCI, said: “We’re thrilled to welcome Laura to further strengthen our global CLO franchise and expand our liquids business across Europe. We believe our momentum in these ar
AMINA Becomes the First Crypto Banking Group to Receive a MiCA License Through Its Austrian Subsidiary3.11.2025 13:04:00 CET | Press release
The Swiss banking group’s Austrian subsidiary is one of the first companies to be MiCAR-licensed by the Austrian FMA. Putting it in a strong position for market launch and accelerated EU expansion. AMINA Bank AG (“AMINA Bank”) today announced that its newly established subsidiary, AMINA (Austria) AG (“AMINA EU”), has received a Crypto-Asset Service Provider (CASP) license from Austria’s Financial Market Authority (FMA) under the Markets in Crypto-Assets (MiCAR) framework. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103510417/en/ AMINA Expands into the EU The FMA’s approval paves the way for AMINA EU’s launch, with regulated crypto trading, custody, and portfolio management services, as well as crypto staking, to be introduced at launch. These offerings will be available to professional investors, including family offices, corporates, financial institutions, and more. AMINA EU, an FMA-licensed crypto-asset service provi
TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation3.11.2025 13:02:00 CET | Press release
Imagine a traveler’s perfect day planning itself, rerouting around a rainstorm, prompting a café to add staff before the lunch rush, suggesting a quiet gallery when crowds swell. This is the promise of Agentic Tourism, an AI-powered operating model introduced in a new white paper by TOURISE and Globant, a digitally native company that helps organizations thrive in a digital and AI-powered future, with strategic contribution from Kearney. The report, titled Tourism’s AI Takeover: Reinventing Travel through Agentic Tourism, presents a practical framework for transforming the tourism experience, making it more seamless, intelligent, and emotionally resonant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251103162356/en/ TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation In 2024, tourism generated 10.9 trillion dollars, nearly 10 percent of global GDP,
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization3.11.2025 13:00:00 CET | Press release
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination ScheduleQDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease ExposureTakeda is Expanding Global Access to QDENGA in Partnership with National Immunization Programs, Private Payors and Public Health Coalitions, with 18.6 Million Doses Distributed in 11 Endemic Countries Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. This is consistent with its approved indications in multiple countries worldwide, which could simplify vaccination schedules and increase adherence. “We ar
SK Capital Completes Acquisition of LISI Group’s Medical Division and Launches New Platform as Precera Medical3.11.2025 12:30:00 CET | Press release
Dylan Hushka appointed Chief Executive Officer SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the specialty materials, ingredients, and life sciences sectors, has completed the previously announced acquisition of LISI Group’s (Euronext: FII) Medical division (the “Transaction”). The business has relocated its headquarters to Big Lake, Minnesota and has been renamed Precera Medical (“Precera Medical” or the “Company”), marking its emergence as a leading contract development and manufacturing organization (“CDMO”) partner for blue chip medical device original equipment manufacturers (“OEMs”) and innovators. As part of the Transaction, LISI Group retained a minority stake in the Company. Precera Medical is a leading CDMO focused on the production of high-precision components and assemblies serving global medical device OEMs. The Company transforms complex designs into reliable, manufacturable solutions for the most demanding applications includ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
